mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2014-01, Vol.28 (1), p.203-206
Hauptverfasser:	Guo, F, Li, J, Zhang, S, Du, W, Amarachintha, S, Sipple, J, Phelan, J, Grimes, H L, Zheng, Y, Pang, Q
Format:	Artikel
Sprache:	eng
Schlagworte:	631/337/1427/2566 692/699/67/1059/2326 692/699/67/1059/99 692/699/67/1990/283/2125 Antineoplastic Agents - therapeutic use Apoptosis Cancer Cancer Research Care and treatment Causes of Chemotherapy Complications and side effects Critical Care Medicine DNA Damage DNA repair Fanconi Anemia Complementation Group D2 Protein - genetics Fanconi Anemia Complementation Group D2 Protein - metabolism Gene expression Hematology Humans Intensive Internal Medicine Kinases letter-to-the-editor Letters to the editor Leukemia Leukemia, T-Cell - drug therapy Leukemia, T-Cell - pathology Lymphocytic leukemia Medical prognosis Medicine Medicine & Public Health Oncology Patient outcomes Physiological aspects T cells TOR Serine-Threonine Kinases - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!